Mark is the Vice President, Business Development for NeoLight. Among other executive positions, he has served as CEO of Galena Biopharma (NASDAQ), Apthera, Bayhill Therapeutics and Caylx Therapeutics. Mark’s extensive experience across operational and strategic management in early stage companies led him to his new role at NeoLight. He is an adjunct faculty member at San Jose State University and currently serves as a Director of Targazyme, Inc.
Driving innovation for treating correctable and preventable conditions in the newborn care market